Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXI-109 for Hypertrophic Scar Recurrence
NCT02030275Phase 2Completed
- Sponsor
- Phio Pharmaceuticals
- Start
- Nov 2013
- Primary completion
- Jun 2016
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Hypertrophic Scar (HS) comparing RXI-109 Side with Placebo Side (2 arms). Primary endpoint: Reduction in recurrence of hypertrophic scarring after scar revision surgery at 9 months. Started Nov 2013; status: completed.
02
Drugs
CTGF siRNA
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT02030275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030275.